An anti-EGFR antibody used in the method of the present invention may have any suitable affinity and/or avidity for one or more epitopes contained at least partially in EGFR.
The antibody used binds to human EGFR with an equilibrium dissociation constant (K D) of 10 -8 M or less, more preferably 10 -10 M or less.